Rob Meijers

Rob Meijers has an extensive work experience in the field of biological research. Rob began their career in 2000 as a Postdoctoral Researcher at the Dana-Farber Cancer Institute. In 2006, they moved to Synchrotron SOLEIL as a Staff Scientist. In 2009, they became a Group Leader at EMBL and in 2020 they joined the Institute for Protein Innovation as Director of the Antibody Platform, Interim Executive Director, and Head of Biological Discovery. Rob also became a Scientific Advisory Board Member at Genecorner in 2020. Most recently, in 2021, they joined Harvard Medical School as a Visiting Lecturer.

Rob Meijers obtained their Doctor of Philosophy (Ph.D.) in Structural Biology from the University of Amsterdam in 2001. Before that, they obtained a Masters in Chemistry from the same university in 1996. Rob also attended Murmellius Gymnasium, Alkmaar from 1983 to 1989, where they completed their high school studies.